Overview

A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment

Status:
Not yet recruiting
Trial end date:
2023-02-04
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the pharmacokinetics and safety of cedirogant following oral administration of multiple doses in adult participants with hepatic impairment and normal hepatic function.
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie